Platelet-activating factor acetylhydrolase is mainly associated with electronegative low-density lipoprotein subfraction

被引:87
作者
Benítez, S
Sánchez-Quesada, JL
Ribas, V
Jorba, O
Blanco-Vaca, F
González-Sastre, F
Ordóñez-Llanos, J
机构
[1] Hosp Santa Creu & Sant Pau, Serv Bioquim, E-08025 Barcelona, Spain
[2] Hosp Santa Creu & Sant Pau, Inst Recerca, E-08025 Barcelona, Spain
[3] Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, E-08193 Barcelona, Spain
关键词
lipoproteins; inflammation; fatty acids;
D O I
10.1161/01.CIR.0000072791.40232.8F
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Electronegative LDL [LDL(-)], a modified subfraction of LDL present in plasma, induces the release of interleukin-8 and monocyte chemotactic protein-1 from cultured endothelial cells. Methods and Results - We demonstrate that platelet-activating factor acetylhydrolase (PAF-AH) is mainly associated with LDL(-). LDL(-) had 5-fold higher PAF-AH activity than the nonelectronegative LDL subfraction [LDL(+)] in both normolipemic and familial hypercholesterolemic subjects. Western blot analysis after SDS-PAGE confirmed these results, because a single band of 44 kDa corresponding to PAF-AH appeared in LDL(-) but not in LDL(+). Nondenaturing polyacrylamide gradient gel electrophoresis demonstrated that PAF-AH was bound to LDL(-) regardless of LDL size. In accordance with the above findings, nonesterified fatty acids, a cleavage product of PAF-AH, were increased in LDL(-) compared with LDL(+). Conclusions - The high PAF-AH activity observed in LDL(-) could be related to the proinflammatory activity of these lipoproteins toward cultured endothelial cells.
引用
收藏
页码:92 / 96
页数:5
相关论文
共 30 条
[1]   Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein (a) in comparison with low density lipoprotein [J].
Blencowe, C ;
Hermetter, A ;
Kostner, GM ;
Deigner, HP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (52) :31151-31157
[2]   Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages [J].
Carpenter, KLH ;
Dennis, IF ;
Challis, IR ;
Osborn, DP ;
Macphee, CH ;
Leake, DS ;
Arends, MJ ;
Mitchinson, MJ .
FEBS LETTERS, 2001, 505 (03) :357-363
[3]   Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase:: a potential new risk factor for coronary artery disease [J].
Caslake, MJ ;
Packard, CJ ;
Suckling, KE ;
Holmes, SD ;
Chamberlain, P ;
Macphee, CH .
ATHEROSCLEROSIS, 2000, 150 (02) :413-419
[4]  
De Castellarnau C, 2000, ARTERIOSCL THROM VAS, V20, P2281
[5]   Cytotoxic electronegative LDL subfraction is present in human plasma [J].
Demuth, K ;
Myara, I ;
Chappey, B ;
Vedie, B ;
PechAmsellem, MA ;
Haberland, ME ;
Moatti, N .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1996, 16 (06) :773-783
[6]   Pefabloc, 4-[2-aminoethyl]benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible inhibitor of PAF-degrading acetylhydrolase [J].
Dentan, C ;
Tselepis, AD ;
Chapman, MJ ;
Ninio, E .
BIOCHIMICA ET BIOPHYSICA ACTA-LIPIDS AND LIPID METABOLISM, 1996, 1299 (03) :353-357
[7]  
HODIS HN, 1994, J LIPID RES, V35, P669
[8]   DISTRIBUTION OF PAF-ACETYLHYDROLASE ACTIVITY IN HUMAN PLASMA LOW-DENSITY-LIPOPROTEIN SUBFRACTIONS [J].
KARABINA, SAP ;
LIAPIKOS, TA ;
GREKAS, G ;
GOUDEVENOS, J ;
TSELEPIS, AD .
BIOCHIMICA ET BIOPHYSICA ACTA-LIPIDS AND LIPID METABOLISM, 1994, 1213 (01) :34-38
[9]   Lipoprotein-associated PLA2 inhibition -: a novel, non-lipid lowering strategy for atherosclerosis therapy [J].
Leach, CA ;
Hickey, DMB ;
Ife, RJ ;
Macphee, CH ;
Smith, SA ;
Tew, DG .
FARMACO, 2001, 56 (1-2) :45-50
[10]   Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein:: use of a novel inhibitor [J].
Macphee, CH ;
Moores, KE ;
Boyd, HF ;
Dhanak, D ;
Ife, RJ ;
Leach, CA ;
Leake, DS ;
Milliner, KJ ;
Patterson, RA ;
Suckling, KE ;
Tew, DG ;
Hickey, DMB .
BIOCHEMICAL JOURNAL, 1999, 338 :479-487